SNX16 is overexpressed in CRC, and overexpression of SNX16 is associated with poor prognosis. (A, B) SNX16 mRNA expression was analyzed using data from the Kaiser colon cohort, Hong colorectal cohort and GEO dataset (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE18105, http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE32323, and http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE44861). **P < 0.01, ***P < 0.001. (C) qRT‐PCR analysis of SNX16 mRNA expression in 20 paired human CRC tissues. SNX16 levels were quantified relative to matched adjacent nontumor tissues and were normalized to GAPDH levels. The data are presented as the mean ± SEMs of three independent experiments. Student's t‐test was performed. **P < 0.01. (D) Western blot analysis of SNX16 protein expression in nine paired CRC tissues and adjacent normal tissues. Tubulin was used as an internal control. (E) IHC analysis of the SNX16 protein in CRC tissues and adjacent normal intestinal epithelium tissues. Representative images of the staining are shown. ***P < 0.001. Scale bar, 200 μm (4×), 50 μm (20×). (F) Kaplan–Meier analysis of the overall survival of CRC patients based on the expression level of SNX16 mRNA in the GEO dataset http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE17538 (six patients were not included in the analysis due to a lack of follow‐up data). (G–J) Kaplan–Meier analysis of overall survival of patients in stages I, II, III, and IV after stratification by TNM stage.